FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3100538981> ?p ?o ?g. }

• W3100538981 abstract "Background The ongoing SURPASS trial ( NCT04044859 ) evaluates safety and efficacy of next-generation ADP-A2M4CD8 SPEAR T-cells co-expressing the CD8α co-receptor with the engineered MAGE-A4 c1032 T cell receptor (TCR). Methods First-in-human trial in HLA-A*02 positive patients (pts) with advanced cancers expressing MAGE-A4 antigen by immunohistochemistry. Eligible pts undergo apheresis, T-cells are isolated, transduced with a Lentiviral vector containing the MAGE-A4 c1032 TCR and CD8α co receptor, and expanded. Expansion, transduction level, cellular composition and function of the manufactured product (MP) are assessed in vitro. Prior to infusion, pts receive lymphodepletion with fludarabine 30 mg/m 2 /day for 4 days and cyclophosphamide 600 mg/m 2 /day for 3 days. Results As of 16 July 2020, 5 pts (1 with MRCLS, 2 with esophagogastric junction [EGJ] cancers, 1 with ovarian cancer, and 1 with head and neck cancer) were treated with ADP-A2M4 CD8 (range ~1 to 5.7 billion transduced cells). No DLTs or SAEs have been reported. To date, 1 pt with EGJ cancer had a partial response (PR per RECIST) and has had progression-free survival >6 months. One pt with head and neck cancer also had a PR. All other pts have had best overall response of stable disease.MP expanded by an average of 15.3 fold during manufacturing (range 5.9 to 25.6-fold). On average, 43% of T-cells in the MP expressed the TCR (range 23 to 63%). The fraction of CD4 + cells in the final MP varied (range 45 to 84%). Co-expression of the MAGE-A4 TCR and CD8α in CD4 + T-cells in the patient MP enabled CD4 + T-cells to kill tumor target cells directly in vitro. MAGE-A4 expression in tumor biopsies varied (H-score range 55 to 300). Transduced T-cells were detected in peripheral blood of all pts. IFN-gamma increased transiently in the serum of 1 pt who responded. Conclusions ADP-A2M4CD8 SPEAR T-cells have shown an acceptable safety profile and pts with EGJ cancer and head and neck cancer have demonstrated evidence of antitumor activity. Translational data and early clinical results indicate that co-expression of the CD8α co-receptor on CD4 + SPEAR T-cells may increase the potency of the product by conferring additional killing activity to the helper T-cell subset. This dose escalation trial is ongoing and updated clinical and translational data will be presented. Trial Registration NCT04044859 Ethics Approval The trial was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines and was approved by local authorities. An independent ethics committee or institutional review board approved the clinical protocol at each participating center. All the patients provided written informed consent before study entry." @default.
• W3100538981 created "2020-11-23" @default.
• W3100538981 creator A5008158683 @default.
• W3100538981 creator A5010235397 @default.
• W3100538981 creator A5020721846 @default.
• W3100538981 creator A5025781878 @default.
• W3100538981 creator A5026095888 @default.
• W3100538981 creator A5038315335 @default.
• W3100538981 creator A5041513953 @default.
• W3100538981 creator A5041740726 @default.
• W3100538981 creator A5042255336 @default.
• W3100538981 creator A5046219779 @default.
• W3100538981 creator A5047132686 @default.
• W3100538981 creator A5047292923 @default.
• W3100538981 creator A5048380048 @default.
• W3100538981 creator A5056234211 @default.
• W3100538981 creator A5057950514 @default.
• W3100538981 creator A5069460930 @default.
• W3100538981 creator A5070244587 @default.
• W3100538981 creator A5070881158 @default.
• W3100538981 creator A5072313658 @default.
• W3100538981 creator A5074821198 @default.
• W3100538981 creator A5077751908 @default.
• W3100538981 creator A5080650099 @default.
• W3100538981 creator A5086524207 @default.
• W3100538981 date "2020-11-01" @default.
• W3100538981 modified "2023-10-15" @default.
• W3100538981 title "379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor" @default.
• W3100538981 doi "https://doi.org/10.1136/jitc-2020-sitc2020.0379" @default.
• W3100538981 hasPublicationYear "2020" @default.
• W3100538981 type Work @default.
• W3100538981 sameAs 3100538981 @default.
• W3100538981 citedByCount "4" @default.
• W3100538981 countsByYear W31005389812021 @default.
• W3100538981 countsByYear W31005389812022 @default.
• W3100538981 crossrefType "journal-article" @default.
• W3100538981 hasAuthorship W3100538981A5008158683 @default.
• W3100538981 hasAuthorship W3100538981A5010235397 @default.
• W3100538981 hasAuthorship W3100538981A5020721846 @default.
• W3100538981 hasAuthorship W3100538981A5025781878 @default.
• W3100538981 hasAuthorship W3100538981A5026095888 @default.
• W3100538981 hasAuthorship W3100538981A5038315335 @default.
• W3100538981 hasAuthorship W3100538981A5041513953 @default.
• W3100538981 hasAuthorship W3100538981A5041740726 @default.
• W3100538981 hasAuthorship W3100538981A5042255336 @default.
• W3100538981 hasAuthorship W3100538981A5046219779 @default.
• W3100538981 hasAuthorship W3100538981A5047132686 @default.
• W3100538981 hasAuthorship W3100538981A5047292923 @default.
• W3100538981 hasAuthorship W3100538981A5048380048 @default.
• W3100538981 hasAuthorship W3100538981A5056234211 @default.
• W3100538981 hasAuthorship W3100538981A5057950514 @default.
• W3100538981 hasAuthorship W3100538981A5069460930 @default.
• W3100538981 hasAuthorship W3100538981A5070244587 @default.
• W3100538981 hasAuthorship W3100538981A5070881158 @default.
• W3100538981 hasAuthorship W3100538981A5072313658 @default.
• W3100538981 hasAuthorship W3100538981A5074821198 @default.
• W3100538981 hasAuthorship W3100538981A5077751908 @default.
• W3100538981 hasAuthorship W3100538981A5080650099 @default.
• W3100538981 hasAuthorship W3100538981A5086524207 @default.
• W3100538981 hasConcept C126322002 @default.
• W3100538981 hasConcept C143998085 @default.
• W3100538981 hasConcept C147483822 @default.
• W3100538981 hasConcept C154317977 @default.
• W3100538981 hasConcept C167672396 @default.
• W3100538981 hasConcept C185592680 @default.
• W3100538981 hasConcept C19317047 @default.
• W3100538981 hasConcept C202751555 @default.
• W3100538981 hasConcept C203014093 @default.
• W3100538981 hasConcept C2776090121 @default.
• W3100538981 hasConcept C2776694085 @default.
• W3100538981 hasConcept C2776755627 @default.
• W3100538981 hasConcept C2779263901 @default.
• W3100538981 hasConcept C55493867 @default.
• W3100538981 hasConcept C71924100 @default.
• W3100538981 hasConcept C8891405 @default.
• W3100538981 hasConcept C90924648 @default.
• W3100538981 hasConceptScore W3100538981C126322002 @default.
• W3100538981 hasConceptScore W3100538981C143998085 @default.
• W3100538981 hasConceptScore W3100538981C147483822 @default.
• W3100538981 hasConceptScore W3100538981C154317977 @default.
• W3100538981 hasConceptScore W3100538981C167672396 @default.
• W3100538981 hasConceptScore W3100538981C185592680 @default.
• W3100538981 hasConceptScore W3100538981C19317047 @default.
• W3100538981 hasConceptScore W3100538981C202751555 @default.
• W3100538981 hasConceptScore W3100538981C203014093 @default.
• W3100538981 hasConceptScore W3100538981C2776090121 @default.
• W3100538981 hasConceptScore W3100538981C2776694085 @default.
• W3100538981 hasConceptScore W3100538981C2776755627 @default.
• W3100538981 hasConceptScore W3100538981C2779263901 @default.
• W3100538981 hasConceptScore W3100538981C55493867 @default.
• W3100538981 hasConceptScore W3100538981C71924100 @default.
• W3100538981 hasConceptScore W3100538981C8891405 @default.
• W3100538981 hasConceptScore W3100538981C90924648 @default.
• W3100538981 hasLocation W31005389811 @default.
• W3100538981 hasOpenAccess W3100538981 @default.
• W3100538981 hasPrimaryLocation W31005389811 @default.
• W3100538981 hasRelatedWork W14186601 @default.
• W3100538981 hasRelatedWork W16058864 @default.
• W3100538981 hasRelatedWork W19219843 @default.
• W3100538981 hasRelatedWork W20730027 @default.

• next